These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15658586)

  • 1. [Drug-eluting stents in coronary arteries. The risk of restenosis is drastically reduced].
    Tornvall P
    Lakartidningen; 2004 Dec; 101(51-52):4175. PubMed ID: 15658586
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents: preventing restenosis.
    Slavin L; Chhabra A; Tobis JM
    Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment and prevention of restenosis after percutaneous coronary intervention. Balloons, stents, radioactive rays and drug-releasing stents].
    Maeng M; Thuesen L; Andersen HR
    Ugeskr Laeger; 2005 Aug; 167(33):3030-2. PubMed ID: 16109244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left main coronary artery stenting: crossing the Rubicon.
    Alfonso F
    J Am Coll Cardiol; 2009 May; 53(19):1769-72. PubMed ID: 19422983
    [No Abstract]   [Full Text] [Related]  

  • 10. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern strategies to prevent coronary restenosis.
    Chieffo A; Stankovic G; Colombo A
    Ital Heart J; 2002 Jun; 3 Suppl 4():9S-15S. PubMed ID: 12116826
    [No Abstract]   [Full Text] [Related]  

  • 12. Peeling-off labels mounting evidence for benefit of drug-eluting stents with off-label use.
    Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2007 Nov; 50(21):2037-8. PubMed ID: 18021869
    [No Abstract]   [Full Text] [Related]  

  • 13. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological aspects of radiation and drug-eluting stents for the prevention of restenosis.
    Sindermann JR; Verin V; Hopewell JW; Rodemann HP; Hendry JH
    Cardiovasc Res; 2004 Jul; 63(1):22-30. PubMed ID: 15194458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
    Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
    Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous coronary intervention and drug-eluting stents.
    Yang YM; Moussa I
    CMAJ; 2005 Feb; 172(3):323-5. PubMed ID: 15684110
    [No Abstract]   [Full Text] [Related]  

  • 18. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
    Gil RJ
    Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-eluting stent update 2007: part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease).
    Colombo A; Chieffo A
    Circulation; 2007 Sep; 116(12):1424-32. PubMed ID: 17875983
    [No Abstract]   [Full Text] [Related]  

  • 20. Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents.
    Yarkoni A; Brodsky A; Sabapathy R; Pershad A
    Indian Heart J; 2008; 60(3):195-9. PubMed ID: 19240306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.